Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Soo-Rim, Jung Yun Jae, Lee Hwa-Yong
Аннотация
Adult stem cell therapies are advancing, yet inconsistent clinical benefit indicates that in vitro potency only partially predicts in vivo performance. Framing efficacy through a systems lens, this review integrates three interlocking levers: (i) cell-intrinsic programs (tissue imprint, transcriptional/epigenetic state, senescence and metabolic fitness), (ii) microenvironmental constraints and designable cues, and (iii) pre- and post-delivery engineering interventions. We highlight how spatially organized biofabrication-especially 3D bioprinting that tunes geometry, stiffness, and factor presentation-converts a simple cell infusion into an architected niche that stabilizes survival, aligns angiogenesis, and accelerates functional integration. We also synthesize optimization levers spanning biochemical/cytokine licensing, hypoxic and mechanical conditioning, genetic/epigenetic programming, and extracellular-vesicle-centered strategies; exemplar platforms show that 3D culture and printing can amplify small EV yield and pro-regenerative content, translating to enhanced vascularization and repair in vivo. Translationally, early- and mid-phase studies show adult stem cells -particularly MSCs-are broadly deliverable with acceptable safety; however, heterogeneity in sourcing, manufacture, dose/route, endpoints, and follow-up undermines comparability, meta-analysis, and payer confidence. We outline a path toward adequately powered, multicenter randomized trials under harmonized controls and mechanism-linked potency assays with standardized clinical and biomarker endpoints. Finally, we examine the regulatory architecture: divergent definitions (manipulation, homologous use), GMP/GTP interpretations, and registry opacity enable uneven evidentiary thresholds and, at times, unregulated offerings-conditions that demand convergence on technical standards, explicit oversight transparency, and risk-based enforcement. Throughout, mesenchymal stem/stromal cells (MSCs) serve as the principal exemplar of adult stem cells, with other adult stem cell populations cited to show that these principles generalize across cell types.